Tβ4 Shows Potential as a Combination Treatment for Diabetes-Induced Complications of the Cornea
Retrieved on:
Wednesday, May 4, 2022
Thymosin beta-4, T4, U.S. Securities and Exchange Commission, Forward-looking statement, Research to Prevent Blindness, Private Securities Litigation Reform Act, University, Company, Hyperglycemia, Annual report, Physician, ARVO, Research, Security (finance), Association, Clinical trial, Risk, OTCQB, Patent, Association for Research in Vision and Ophthalmology, VIP, National, Form 10-K, Regeneration, Cornea, Method, University of Central Florida College of Optics and Photonics, Visual impairment, Diabetes, Wayne State University School of Medicine, Mansoura University, SEC, Vasoactive intestinal peptide, Pharmaceutical industry, EU, Vision, Ophthalmology
Furthermore, T4 strongly establishes its role as an adjunctive treatment for diabetic corneal impediments with no side effects, thereby easing the disadvantages of present methods of [eye] care," according to the research team.
Key Points:
- Furthermore, T4 strongly establishes its role as an adjunctive treatment for diabetic corneal impediments with no side effects, thereby easing the disadvantages of present methods of [eye] care," according to the research team.
- The research was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2022 meeting, held May 1-4, 2022, in Denver, Colorado.
- RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (T4) and its constituent fragments, for tissue and organ protection, repair, and regeneration.
- The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.